Prosecution Insights
Last updated: November 12, 2026
Application No. 18/828,394

LAMP Constructs

Non-Final OA §DOUBLEPATENT
Filed
Sep 09, 2024
Priority
Apr 22, 2017 — provisional 62/488,741 +6 more
Examiner
ZOU, NIANXIANG
Art Unit
1671
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Immunomic Therapeutics Inc.
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
89%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
501 granted / 783 resolved
+4.0% vs TC avg
Strong +25% interview lift
Without
With
+25.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
49 currently pending
Career history
834
Total Applications
across all art units

Office Action

§DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Acknowledgement is hereby made of receipt and entry of the communication filed on Dec. 19, 2024. Claims 24-41 are pending and currently examined. Information Disclosure Statement The information disclosure statement submitted on Dec. 19, 2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner. The IDS contains Foreign Patent Documents and Non-Patent Literature Documents that are not in English language. The documents not provided in English language are considered only to the extent of the Examiner’s capacity of the related for foreign language and the English language submission. An initialed and dated copy of Applicant’s IDS form is attached to the instant Office action. Double Patenting Rejection The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/forms/. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 24-41 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-23 of US Patent 11,203,629. Although the conflicting claims are not identical, they are not patentably distinct from each other. Both sets of claims encompass a LAMP construct comprising a heterologous antigenic domain placed between two homology domains in the luminal region of the LAMP protein. The differences/correlations between the two sets of claims include: (1) the instant claims require that the LAMP construct comprises the two homology domains of a LAMP-1 protein, while only the reference claims 5-8 specify LAMP-1 and other reference claims are generic in the LAMP protein types; (2) instant claims specify a polynucleotide encoding the LAMP construct, while reference claims 1-10 and 18-23 specify polypeptide of the LAMP construct and only claims 11-14 specify an encoding polynucleotide; (3) instant claims 28-29 and 31-35 specify SEQ ID NO: 1 for the LAMP-1 protein, while reference claims 6-7 specify SEQ ID NO: 1 for LAMP-1; (4) instant claims 31-35 specify amino acid positions in SEQ ID NO: 1 flanking structural regions of the LAMP-1 protein, while reference claims are silent on such positions; (5) instant claims 37, 39 and 40 respectively specify a self-replicating RNA viral vector, an isolated antigen-presenting cell, and more specifically dendritic cell, comprising the polynucleotide encoding the LAMP construct, while references claims are silent on these limitations; and (6) the instant claims require that the LAMP construct further comprises a transmembrane domain of a LAMP protein, a cytoplasmic tail of a LAMP protein, and a signal sequence and the relative position of the transmembrane and cytoplasmic domain, while this limitation is only partially specified by some reference claims. Among the above 6 differences/correlation between the two sets of claims, only points (4) and (5) are absent or partially absent in reference claims. Regarding (4), since the amino acid positions separating the recited structural features of the LAMP-1 protein with SEQ ID NO: 1, one of skill in the art would have envisaged that the LAMP-1 protein with SEQ ID NO: 1 recited in reference claims 6-7 would inherently have the same structural features with the same amino acid boundaries. Regarding (5), McCullough et al. (Vaccines 2014, 2, 735-754) reviews studies on self-amplifying replicon RNA vaccine delivery to dendritic cells by synthetic nanoparticles. The review presents how such advances are being applied to the delivery of a new form of RNA vaccine, replicons (RepRNA) carrying inserted foreign genes of interest encoding vaccine antigens. Approaches have been developed for delivery to DCs, leading to the translation of the RepRNA and encoded vaccine antigens both in vitro and in vivo. The review relates the DC endocytic pathways to immune response induction, and the potential advantages for these self-replicating RNA vaccines in the near future. See Abstract. Based on teachings of McCullough, it is known practice to include polynucleotide encoding antigen genes in viral RNA replicons and to introduce such expression constructs into dendritic cells. Therefore, one of skill in the art would have found it obvious to include the polynucleotide encoding the LAMP construct of the reference claims in a viral RNA replicon vector and introduce the vector into dendritic cells for further applications, arriving at the instant claims 37, 39 and 40. Accordingly, claims 24-41 are unpatentable over claims 1-23 of US Patent 11,203,629. Claims 24-41 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-31 of US Patent 11,773,153. Although the conflicting claims are not identical, they are not patentably distinct from each other. Both sets of claims encompass a LAMP construct comprising a heterologous antigenic domain placed between the two homology domains in the LAMP-1 protein. The differences/correlations between the two sets of claims include: (1) reference claims 2-5, 8-13 and 28-31 specify structural feature of the LAMP-1 protein, specifically the LAPM-1 with SEQ ID NO: 1, correlating to instant claims 25-35; (2) reference claims 6-7 specify a linker between the two homology domains and the antigenic domain, correlating to instant claims 26-27; (3) reference claims 14-17, 19-20 specify a polynucleotide encoding the claimed LAMP-1 construct, correlating to instant claims 24-41; (4) reference claim 21-27 specify a method of administering the LAMP-1 construct, correlating to instant claim 41; (5) instant claims 37, 39 and 40 respectively specify a self-replicating RNA viral vector, an isolated antigen-presenting cell, and more specifically dendritic cell, comprising the polynucleotide encoding the LAMP construct, while references claims are silent on these limitations; and (6) the instant claims require that the LAMP construct further comprises a transmembrane domain of a LAMP protein, a cytoplasmic tail of a LAMP protein, and a signal sequence and the relative position of the transmembrane and cytoplasmic domain, while this limitation is only partially specified by some reference claims. Among the above 6 differences/correlation between the two sets of claims, only point (5) is absent or partially absent in reference claims. McCullough et al. (Vaccines 2014, 2, 735-754) reviews studies on self-amplifying replicon RNA vaccine delivery to dendritic cells by synthetic nanoparticles. The review presents how such advances are being applied to the delivery of a new form of RNA vaccine, replicons (RepRNA) carrying inserted foreign genes of interest encoding vaccine antigens. Approaches have been developed for delivery to DCs, leading to the translation of the RepRNA and encoded vaccine antigens both in vitro and in vivo. The review relates the DC endocytic pathways to immune response induction, and the potential advantages for these self-replicating RNA vaccines in the near future. See Abstract. Based on teachings of McCullough, it is known practice to include polynucleotide encoding antigen genes in viral RNA replicons and to introduce such expression constructs into dendritic cells. Therefore, one of skill in the art would have found it obvious to include the polynucleotide encoding the LAMP construct of the reference claims in a viral RNA replicon vector and introduce the vector into dendritic cells for further applications, arriving at the instant claims 37, 39 and 40. Accordingly, claims 24-41 are unpatentable over claims 1-31 of US Patent 11,773,153. Claims 24-41 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-28 of US Patent 12,116,396. Although the conflicting claims are not identical, they are not patentably distinct from each other. Both sets of claims encompass a polynucleotide encoding a LAMP construct comprising a heterologous antigenic domain placed between two homology domains in the LAMP protein. The differences/correlations between the two sets of claims include: (1) reference claims 1-6, 18-22 and 28 are generic in the LAMP protein, references claims 7-17 and 23-27 specify LAMP-1, while all instant claims specify LAMP-1; (2) reference claims 4-5 specify a linker, correlating to instant claims 26-27; (3) references claims 8-9 and 11-17 specify structural features of LAMP-1 protein, specifically the LAPM-1 with SEQ ID NO: 1, correlating to instant claims 25-35; (4) reference claim 28 specifies a method of administering the LAMP-1 construct, correlating to instant claim 41; (5) reference claims 18-27 specify a self-replicating RNA viral vector, and/or an isolated antigen-presenting cell, and more specifically dendritic cell, comprising the polynucleotide encoding the LAMP construct, correlating to instant claims 37, 39 and 40; and (6) the instant claims require that the LAMP construct further comprises a transmembrane domain of a LAMP protein, a cytoplasmic tail of a LAMP protein, and a signal sequence and the relative position of the transmembrane and cytoplasmic domain, while this limitation is only partially specified by some reference claims. Since the two sets of claims encompass each other in scopes, the instant claims are obvious over the reference claims. Accordingly, claims 24-41 are unpatentable over claims 1-28 of US Patent 12,116,396. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIANXIANG (NICK) ZOU whose telephone number is (571)272-2850. The examiner can normally be reached on Monday - Friday, 8:30 am - 5:00 pm, EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MICHAEL ALLEN, on (571) 270-3497, can be reached. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NIANXIANG ZOU/Primary Examiner, Art Unit 1648
Read full office action

Prosecution Timeline

Sep 09, 2024
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760378
NON-REPLICATIVE TRANSDUCTION PARTICLES WITH ONE OR MORE NON-NATIVE TAIL FIBERS AND TRANSDUCTION PARTICLE-BASED REPORTER SYSTEMS
3y 9m to grant Granted Oct 13, 2026
Patent 12742164
SPECIFIC HOST FACTOR OF HEPATITIS B VIRUS INFECTION, AND USE THEREOF
4y 2m to grant Granted Sep 22, 2026
Patent 12741992
BACTERIAL PILUS PROTEIN COMPLEX FIMGT-DSF STABILIZED PROTEIN COMPLEXES FOR PRODUCING FILAMENTOUS PHAGES
3y 6m to grant Granted Sep 22, 2026
Patent 12721888
IMMUNOGENIC PROBIOTIC COMPOSITIONS AND METHODS OF USE INCLUDING IN VACCINATION
3y 3m to grant Granted Sep 01, 2026
Patent 12702706
METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS
2y 6m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
89%
With Interview (+25.2%)
Low
PTA Risk
Based on 783 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month